Nuance Pharma

Your privacy is very important to us.When you visit our website,please agree to the use of all cookies.For more information about personal data processing,please go to Privacy Statement.

  • shouyebanner1.jpg shouyebanner1shouji.jpg

    We Are A Specialty Care
    Biopharma Company

    Committed To Bringing Transformational Therapies
    To Patients In China And Asia

  • shouyebanner2.svg shouyebanner2shouji.svg

    Fit For Purpose

    We Transcend Clinical Application Insights That Drive Our
    Clinical Development Strategy Through A Dual Wheel Model
    Of Our Integrated Commercial Platform And Late Stage
    Clinical Pipeline

  • abanner01.jpg shouyebanner3shouji.jpg

    Specialty Care
    Boutique

    We Focus On Developing First-in-Class Innovative Pipeline
    To Address Unmet Medical Needs In Respiratory For The
    Vast Patient Community In Asia

  • shouyebanner4.jpg shouyebanner4shouji.jpg

    Asia Pac Vision

    We Are Passionate About Exploring APAC Business Opportunities
    And Have Substantive Progress In Our Asian Expansion Strategy
    Bringing Therapies That Are More Accessible To People In China And Asia

Our Area Of Focus

We Have Developed A Differentiated Matrix Of Commercial Products And Innovative Pipeline Across Respiratory, Emergency Care, Iron Deficiency Anemia, Pain Management

Highlights

Founded by Mark Lotter in 2014, Nuance deploys the Dual Wheel model that develops a leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia

  • 5PRODUCTS

    COMMERCIAL

  • 4PIPELINE

    LATE STAGE CLINICAL

  • 300+

    EMPLOYEES WORLDWIDE

Our Transformative Journey

  • logo-153.png

    2024

    US FDA approved Ohtuvayre (ensifentrine) for the maintenance treatment of COPD

  • shouyeOurTransformativeJourney-23.png

    2023

    Completed dosing of First Patient in Ensifentrine China phase 3 trial for COPD

  • shouyeOurTransformativeJourney.png

    2022

    Launched nasal spray Bentrio™ in Hong Kong

    Licensed in allergy alleviation / virus prevention nasal spray Bentrio™ from Altamira Therapeutics

  • shouyeOurTransformativeJourney-930.png

    2021

    Licensed in First-in-Class COPD dual MOA PDE 3&4 inhibitor Ensifentrine from Verona Pharma

    Licensed in neonatal RDS drug / device combo Aerofact™ from Aerogen Pharma

    Acquired Sino Health with access to 3 emergency care products and a GSP license in Zhuhai

  • shouyeOurTransformativeJourney-600.png

    2020

    Licensed in post-operative pain product Ketorolac (NTM-001) from Neumentum

    Raised US$ 181 million Series D equity funding


  • shouyeOurTransformativeJourney-495.png

    2019

    Acquired NIFEREX Iron Polysaccharide Complex Capsules

  • shouyeOurTransformativeJourney-666.png

    2018

    Established partnership with Aerogen Pharma on nebulizer device

    Accumulatively raised US$ 80 million equity funding

  • shouyeOurTransformativeJourney-596.png

    2014

    Mr. Mark Lotter founded Nuance Pharma in Shanghai

2024

2023

2022

2021

2020

2019

2018

2014

  • 2024

  • 2023

  • 2022

  • 2021

  • 2020

  • 2019

  • 2018

  • 2014

CONTACT

Suite 639, East Tower, No 1376 Nan Jing West Road, Shanghai. 200040

Copyright 2023 NUANCE BIOTECH reserved. 沪ICP备17029781号-4